The COURAGE trial showed no substantial difference in cardiovascular outcomes among patients who received either optimal medical therapy or optimal therapy plus a percutaneous intervention. Dr. William Weintraub, professor of medicine at Chrisitana Care Health System in Newark, Delaware, describes his cost-benefit analysis of this trial and how cost effectiveness should be measured and evaluated in this patient population. Hosted by Dr. Matthew Sorrentino.
A Cost-Benefit Analysis of Angioplasty
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
The COURAGE trial showed no substantial difference in cardiovascular outcomes among patients who received either optimal medical therapy or optimal therapy plus a percutaneous intervention. Dr. William Weintraub, professor of medicine at Chrisitana Care Health System in Newark, Delaware, describes his cost-benefit analysis of this trial and how cost effectiveness should be measured and evaluated in this patient population. Hosted by Dr. Matthew Sorrentino.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
Episode 2 Part B: Effectively Transferring Over the CKD Patient at the Right Time
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
Level Up Your Skills: Tailoring Management of HF
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?